Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Peptides that interact with GH-releasing pathways, such as CJC-1295 and Ipamorelin, are studied for their ability to influence these processes in controlled laboratory environments
Evidence level is high based on confirmed Phase 3 data
Are both drugs FDA-approved for weight loss
158 (CDC, 2021)
The Fat Loss Mechanism The proposed fat loss mechanism of 5-amino-1MQ operates through several interrelated effects: NNMT inhibition preserves SAM and NAD+ pools Increased NAD+ supports sirtuin activity and mitochondrial function Reduced lipogenesis adipocyte fatty acid synthesis is decreased Enhanced adipocyte metabolism improved adipose tissue function Selective effect on adipocytes relative sparing of other tissues Preclinical studies have shown that 5-amino-1MQ treatment in mice produces: Reduced body fat mass Improved insulin sensitivity Preserved lean mass Favorable effects on liver fat in diet-induced obesity models The Human Clinical Trials Picture As of 2026, human clinical trial activity for 5-amino-1MQ is emerging but not yet mature
Drink at least 30 minutes before exercise or as directed by your healthcare professional
US$ 25.70
US$ 22.97
US$ 29.82
US$ 20.81
US$ 21.30
US$ 25.93
